← back to search

Bin Zhao

Fujian Medical University · US
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, and CAR-T cell therapy research.
h-index
21
citations
3,798
works
112
NIH funding
primary concept
Medicine
email

Recent publications

Healthy lifestyle partly mediates the association between self-rated health and risk of overall and cause-specific mortality
BMC Medicine 2025cited by 4position: middledoi
Blockade of CCR5<sup>+</sup> T Cell Accumulation in the Tumor Microenvironment Optimizes Anti‐TGF‐β/PD‐L1 Bispecific Antibody
Advanced Science 2024cited by 20position: middledoi
The correlation between KRAS and TP53 gene mutations and early growth of pulmonary nodules
Research Square 2024cited by 0position: firstdoi
Exploiting innate immunity for cancer immunotherapy
Molecular Cancer 2023cited by 212position: middledoi
Effect of dietary patterns on dental caries among 12–15 years-old adolescents: a cross-sectional survey
BMC Oral Health 2023cited by 9position: middledoi
Increased expression of ECT2 predicts the poor prognosis of breast cancer patients
Experimental Hematology and Oncology 2022cited by 27position: middledoi
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
Journal of Clinical Oncology 2021cited by 1,085position: middledoi
Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407
Journal of Thoracic Oncology 2021cited by 182position: middledoi
Tumor-Infiltrating Cytotoxic T Cells and Tumor-Associated Macrophages Correlate With the Outcomes of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
Frontiers in Oncology 2021cited by 39position: middledoi
Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
Therapeutic Advances in Medical Oncology 2020cited by 223position: firstdoi
Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC
Journal of Thoracic Oncology 2020cited by 181position: middledoi
Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer
Therapeutic Advances in Medical Oncology 2020cited by 16position: firstdoi
Randomized phase III study of first-line pembrolizumab plus pemetrexed/platinum followed by pembrolizumab and maintenance olaparib versus pemetrexed in patients with metastatic nonsquamous non-small cell lung cancer (NSCLC): KEYLYNK-006.
Journal of Clinical Oncology 2020cited by 9position: middledoi
Risk of fatal adverse events in cancer patients treated with sunitinib
Critical Reviews in Oncology/Hematology 2019cited by 14position: firstdoi
Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
Journal for ImmunoTherapy of Cancer 2019cited by 3position: firstdoi
Incidence and Risk of Fatal Adverse Events in Cancer Patients Treated With Vascular Endothelial Growth Factor Receptor 2-Targeted Agents: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials
Frontiers in Medicine 2019cited by 2position: firstdoi
Corrigendum to “Incidence and clinical parameters associated with eribulin mesylate-induced peripheral neuropathy” [Crit. Rev. Oncol./Hematol. 128 (August) (2018) 110–117]
Critical Reviews in Oncology/Hematology 2019cited by 1position: firstdoi
Correction: Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib
Oncotarget 2019cited by 0position: firstdoi
Correction: Incidence and risk of regorafenib-induced hepatotoxicity
Oncotarget 2019cited by 0position: firstdoi
Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
Journal for ImmunoTherapy of Cancer 2018cited by 40position: firstdoi
Impact of clinicopathological characteristics on survival in patients treated with immune checkpoint inhibitors for metastatic melanoma
International Journal of Cancer 2018cited by 14position: firstdoi
Impact of hormone receptor status on the efficacy of HER2-targeted treatment
Endocrine Related Cancer 2018cited by 13position: firstdoi
Incidence and clinical parameters associated with eribulin mesylate-induced peripheral neuropathy
Critical Reviews in Oncology/Hematology 2018cited by 9position: firstdoi
Beclin 1 and LC3 as predictive biomarkers for metastatic colorectal carcinoma
Oncotarget 2017cited by 26position: lastdoi
Incidence and risk of regorafenib-induced hepatotoxicity
Oncotarget 2017cited by 13position: firstdoi
Impact of clinicopathological characteristics on the efficacy of neoadjuvant therapy in patients with human epidermal growth factor receptor‐2‐positive breast cancer
International Journal of Cancer 2017cited by 12position: firstdoi
Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib
Oncotarget 2017cited by 6position: firstdoi
Incidence and risk of eribulin mesylate related hematologic toxicity
Oncotarget 2017cited by 1position: firstdoi
Autophagy-based survival prognosis in human colorectal carcinoma
Oncotarget 2015cited by 44position: lastdoi

Grants

Interfacial Behavior of Stimuli-Responsive Multicomponent Molecular Bottlebrush Polymers
NSF2412257$609,6102024–2028PIRePORTER
Collaborative Research: Directed Assembly of Nanoparticles and Polymers via Co-Crystallization
NSF2414063$129,5522024–2027PIRePORTER
Shape Changing Stimuli-Responsive Multicomponent Molecular Bottlebrushes in Solution and at Interfaces
NSF2004564$550,0002020–2024PIRePORTER
Collaborative Research: Polymer Single Crystal-Assisted "Grafting From": A Versatile Approach towards Multicomponent Polymer Brushes with Well-Defined Architectures and Grafting
NSF1709663$370,9532017–2023PIRePORTER
Stimuli-Responsive Shape-Changing Molecular Brushes
NSF1607076$490,0002016–2021PIRePORTER
Travel Support for an ACS PMSE Symposium Entitled "Hairy Particles: Theory, Synthesis, Behavior, and Applications", September 8-12, 2013, Indianapolis, IN
NSF1322184$4,0002013–2014PIRePORTER
Tuning Aqueous Micellar Gels and Nanoparticle-Containing Hybrid Micellar Gels of Thermosensitive Hydrophilic Block Copolymers
NSF1206385$361,6882012–2017PIRePORTER
Materials World Network: Collaborative Research: Nanoscale Self-Assembly of Well-Defined Binary Mixed Homopolymer Brushes Grafted on Inorganic Particles
NSF1007986$297,0002010–2015PIRePORTER
Active Control of Sol-Gel-Sol Transitions of Aqueous Solutions of Doubly Responsive Hydrophilic Block Copolymers
NSF0906913$330,0002009–2012PIRePORTER
Doubly Thermosensitive Block and Star Copolymers from Living Radical Polymerizations: Synthesis, Phase Transitions, and Applications
NSF0605663$297,0002006–2010PIRePORTER

Frequent collaborators

Hong Zhao · Northwestern University16 papers (2015–2020)Jiaxin Zhao · Northwest A&F University10 papers (2018–2020)Kongming Wu · Drexel University3 papers (2022–2024)Mengke Niu · Huazhong University of Science and Technology3 papers (2022–2024)Ming Yi · Nanchang University3 papers (2022–2024)Qian Chu · Sun Yat-sen University Cancer Center2 papers (2023–2024)Tianye Li · Wenzhou Medical University2 papers (2023–2024)Bilal Piperdi · Merck & Co., Inc., Rahway, NJ, USA (United States)2 papers (2020–2021)Delvys Rodríguez‐Abreu · Universidad de Las Palmas de Gran Canaria2 papers (2021–2021)M. Catherine Pietanza · Merck & Co., Inc., Rahway, NJ, USA (United States)2 papers (2021–2021)Steven Powell · Sanford Health2 papers (2020–2021)Ali Tafreshi · Massachusetts General Hospital2 papers (2021–2021)Mark M. Awad · PCAS (France)2 papers (2020–2021)Corey J. Langer · Pennsylvania Hospital2 papers (2020–2021)Hong Zhao · Qingdao University2 papers (2020–2021)Maopeng Yang · Harbin Medical University2 papers (2015–2017)Yuze Wu · Huazhong University of Science and Technology2 papers (2022–2024)Huanfen Zhao · Hebei General Hospital1 papers (2024–2024)Lu Shi · Qingdao University1 papers (2021–2021) · 1 papers (2025–2025)